NCT04673864View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 17, 2021

Primary Completion Date

March 4, 2021

Study Completion Date

March 30, 2021

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-386

QD, PO

DRUG

D012, D326, D337

QD, PO

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY